Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This clinical trial intends to investigate the safety, tolerability and efficacy of ularitide
on the renal response in patients with liver cirrhosis and refractory ascites for a maximum
exposure duration of 48 hours, through a randomized, placebo-controlled, double-blind,
single-center trial.
Phase:
Phase 2
Details
Lead Sponsor:
University of Aarhus
Collaborators:
Aarhus University Hospital ADS AIPHIA Development Services AG